A Ground-Floor Opportunity in the Next Decade’s Most Disruptive Technology

A Ground-Floor Opportunity in the Next Decade’s Most Disruptive Technology Share This Article Private Briefing with WILLIAM PATALON III, Executive Editor Look Who’s Talking… About Liquid Biopsy Technology I’ve told this story before, but it bears repeating here… Back in April 2015, about a month after I originally recommended “Liquid Biopsy” stock TrovaGene Inc. (Nasdaq: TROV), biotech-sector executive Tina Nova wrote in a Wired magazine essay that the still-in-development cancer-screening technology is “the most exciting thing I’ve seen since I started my career.” Full Story Today’s Markets DJIA 230.24 (1.29%) 18,011.07 NASDAQ 76.72 (1.59%) 4,910.04 S&P 27.88 (1.34%) 2,113.32


Link to Full Article: A Ground-Floor Opportunity in the Next Decade’s Most Disruptive Technology